Table 1.
Demographic and Clinical Characteristics of the Participants
| Characteristic | Patients baseline (n = 120) | Patients follow-up (n = 75) |
|---|---|---|
| Age, y (mean ± SD) | 23.9 ± 5.8 | 25.08 ± 6 |
| Sex, n (%) | ||
| Male | 82 (68.3) | 51 (68) |
| Female | 38 (31.7) | 24 (32) |
| Ethnic group, n (%) | ||
| Caucasian | 113 (94.2) | 69 (92) |
| Hispanic | 3 (2.5) | 2 (2.7) |
| Others | 4 (3.3) | 4 (5.3) |
| Body mass index (mean ± SD) | 24.89 ± 4.04 | 24.63 ± 5.1 |
| Psychiatric history | ||
| DUP (mean ± SD) | 96.95 ± 113.79 | |
| Diagnosis, n (%)* | ||
| Affective psychosis | 22 (18.3) | 24 (32.4) |
| Nonaffective psychosis | 98 (81.7) | 50 (67.6) |
| Antipsychotic medication, n (%) | ||
| Risperidone | 43 (35.8) | 15 (20.5) |
| Aripiprazole | 12 (10.0) | 15 (20.5) |
| Olanzapine | 15 (12.5) | 5 (6.8) |
| Quetiapine | 7 (5.8) | 5 (6.8) |
| Clozapine | 8 (6.7) | 5 (6.8) |
| Ziprasidone | 2 (1.7) | 2 (2.7) |
| Paliperidone | 10 (8.3) | 5 (6.8) |
| None | 23 (19.2) | 21 (28.8) |
| DDD of CPZ eq., (mg) (mean ± SD) | 49.62 ± 127.88 | 39.84 ± 87.85 |
Abbreviations: DDD of CPZ eq., Defined daily dose of chlorpromazine equivalent; DUP, days of untreated psychosis. Comparison between FEP patients at baseline and the follow-up assessed with a t test (age, body mass index) a chi-squared test (gender, diagnosis, medication), the likelihood ratio (ethnic group) and a Mann Whitney U-test (DDD of CPZ eq.). *P = .025.